On Monday, Gilead Sciences reached a noteworthy technical benchmark, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an upgrade to 91, an increase from 88 the day before.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique rating identifies share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks tend to have an RS Rating of above 80 as they launch their biggest runs.
Gilead Sciences is trying to complete a consolidation with a 119.96 buy point. See if the stock can clear the breakout price in heavy trade. It's a later-stage pattern, and investors should be aware that those involve more risk.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 0%.
The company earns the No. 13 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
